ImmuPharma PLC (AIM:IMM, OTC:IMMPF)'s (ImmuPharma PLC (AIM:IMM, OTC:IMMPF), ImmuPharma PLC (AIM:IMM, OTC:IMMPF)) chief executive, Tim McCarthy talks to Proactive London's Katie Pilbeam about their raise of £3.55mln in three separate tranches to fund its research and development portfolio.
A total of £1.2mln will come from Alora Pharmaceuticals, the parent company of ImmuPharma’s partner, Avion Pharmaceuticals.
He talks about their corporate repositioning since the board changes in August and that these have been 'recognised by our long-term shareholder Lanstead.